Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
36.87 USD | -2.46% | -0.35% | +71.33% |
May. 15 | Spyre Therapeutics, Inc. Announces Board Changes | CI |
May. 13 | Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+71.33% | 1.49B | |
+9.58% | 115B | |
+12.41% | 107B | |
-3.49% | 21.6B | |
-12.38% | 22.31B | |
-6.82% | 19.19B | |
-3.35% | 18.23B | |
-38.57% | 17.62B | |
+7.51% | 14.26B | |
+35.67% | 12.37B |
- Stock Market
- Equities
- SYRE Stock
- News Spyre Therapeutics, Inc.
- Piper Sandler Lifts Aeglea BioTherapeutics to Overweight From Neutral, Price Target to $1.50 From $1